MASS icon

908 Devices

4.32 USD
-0.14
3.14%
At close Mar 13, 4:00 PM EDT
After hours
4.37
+0.05
1.16%
1 day
-3.14%
5 days
43.52%
1 month
68.75%
3 months
107.69%
6 months
20.00%
Year to date
97.26%
1 year
-38.72%
5 years
-91.18%
10 years
-91.18%
 

About: 908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.

Employees: 246

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

33% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 21

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

5.64% less ownership

Funds ownership: 53.76% [Q3] → 48.12% (-5.64%) [Q4]

6% less funds holding

Funds holding: 86 [Q3] → 81 (-5) [Q4]

15% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 20

43% less capital invested

Capital invested by funds: $64.9M [Q3] → $36.9M (-$28M) [Q4]

97% less call options, than puts

Call options by funds: $2K | Put options by funds: $66K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$6
39%
upside
Avg. target
$6
39%
upside
High target
$6
39%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Stephens & Co.
Jacob Johnson
33% 1-year accuracy
5 / 15 met price target
39%upside
$6
Overweight
Reiterated
15 Jan 2025

Financial journalist opinion

Based on 9 articles about MASS published over the past 30 days

Positive
Zacks Investment Research
11 hours ago
Best Momentum Stocks to Buy for March 13th
BK, TKOMY and MASS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13, 2025.
Best Momentum Stocks to Buy for March 13th
Neutral
Business Wire
2 days ago
908 Devices Receives $1.7M Order from the Ministry of Health of Ukraine for its Handheld Mass Spec Device
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces that it has received a $1.7 million order from the Ministry of Health of Ukraine for its MX908 handheld mass spectrometry device with Aero module for priority shipment in the first quarter 2025. The devices will be part of an environmental testing kit in a post-war environment and will be used primarily to detect and identify trace substances of hazardous materi.
908 Devices Receives $1.7M Order from the Ministry of Health of Ukraine for its Handheld Mass Spec Device
Positive
Seeking Alpha
1 week ago
908 Devices Makes Key Divestiture (Rating Upgrade)
908 Devices' stock surged after announcing a $70 million desktop portfolio sale, doubling its cash position and improving financial stability. The company will now focus on its handheld device business, expecting 11% to 15% revenue growth in 2025 with acceleration in 2026. MASS management believes losses will be significantly reduced with the new structure, with positive cash flow next year.
908 Devices Makes Key Divestiture (Rating Upgrade)
Positive
Benzinga
1 week ago
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
On Tuesday, Repligen Corporation RGEN purchased 908 Devices Inc.'s MASS desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
Negative
Zacks Investment Research
1 week ago
908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.23 per share a year ago.
908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates
Neutral
Business Wire
1 week ago
908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety crises through the divestiture of its bioprocessing desktop assets to Repligen Corporation. This transac.
908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
Business Wire
1 week ago
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
WALTHAM, Mass., & BOSTON--(BUSINESS WIRE)--Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device.
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Neutral
Business Wire
1 week ago
908 Devices to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the following investor conferences. TD Cowen 45th Annual Healthcare Conference, Boston, MA Fireside chat on Wednesday, March 5 at 9:50 a.m. Eastern Time Leerink Global Healthcare Conference, Miami, FL Fireside chat on Tuesday, March 11 at 1 p.m. Eastern Time Interested parties may access a live and archived webcast of the.
908 Devices to Participate in Upcoming Investor Conferences
Neutral
Business Wire
1 week ago
908 Devices to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the fourth quarter and full year 2024 before market open on Tuesday, March 4, 2025. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devices.
908 Devices to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
Neutral
Business Wire
1 month ago
908 Devices Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced preliminary unaudited financial results for the quarter and full year ended December 31, 2024. Preliminary unaudited revenue for the fourth quarter of 2024 is expected to be approximately $17.2 million, compared to $14.4 million in the fourth quarter of 2023, reflecting reported growth of approximately 20%. Fourth quarter handheld revenues grew.
908 Devices Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
Charts implemented using Lightweight Charts™